Cypherpunk Technologies receives Nasdaq bid-price deficiency notice
Cypherpunk Technologies received a notification from Nasdaq on July 20, 2026, stating that its common stock closing bid price has remained below the $1.00 minimum required by Nasdaq Listing Rule 5550(a)(2) for the last 30 consecutive business days. The company has until January 19, 2027—a 180-day cure period—to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The company may be eligible for an additional 180-calendar-day compliance period if it meets other continued listing requirements on January 19, 2027, and notifies Nasdaq of its intent to cure, including potentially through a reverse stock split.
Key facts
- Notification date: July 20, 2026
- Deficiency: closing bid price below $1.00 per share for 30 consecutive business days
- Compliance deadline: January 19, 2027 (180 days)
- Cure requirement: maintain closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days
- Potential additional compliance period: 180 calendar days if other listing standards are met on January 19, 2027
- Nasdaq rule: Rule 5550(a)(2)
- Possible remedies: reverse stock split or other unspecified options
Why it matters
The deficiency notice creates a compliance deadline that, if unmet, could result in Cypherpunk's delisting from Nasdaq; the company must execute a strategic response—potentially including a reverse stock split—within the next six months to maintain its exchange listing.
Share
Derived from 8-K filed 2026-07-21. Not investment advice. View the source filing on SEC.gov →